Article | January 18, 2022

Selecting Drug Delivery Systems For Higher Doses, Higher Viscosities, And Lower Risk

Source: BD Medical - Pharmaceutical Systems

By: Nicolas Bralet and Megan Lan, MBA, MA

iStock-1319077865-lab-team-computer-research

The development of new parenteral biologics with high-volume, high-viscosity formulations (&GT 1 mL, &GT15 cP) is triggering the need for devices that can deliver these therapies with the ease, safety, and low injection time required for self-injection.1-3 As these formulations come to market, pharmaceutical and biotech companies must make critical device choices from an array of largely unproven options.2 The following article discusses how companies can de-risk their device selection as they bring this new generation of high-volume, high-viscosity biologics to market.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Biosimilar Development? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to:

BD Medical - Pharmaceutical Systems